FOR IMMEDIATE RELEASE

ACS News Service Weekly PressPac: November 03, 2021

A quick, high-yield synthesis of molnupiravir, an investigational COVID antiviral pill


ACS Central Science

As SARS-CoV-2 continues to spread and mutate, it鈥檚 important to identify new treatment options. Molnupiravir is an investigational oral antiviral being developed for the treatment of COVID-19, and has been submitted for review by the U.S. Food and Drug Administration. Researchers now report in聽ACS Central Science聽that they have engineered enzymes to help manufacture the pill, resulting in a much shorter and higher-yielding synthesis than current methods.

Originally developed to treat influenza, molnupiravir works by causing viruses to make errors when copying their own RNA, introducing mutations that inhibit replication. Recently, interim phase 3 clinical trial findings indicated that molnupiravir reduced the risk of hospitalization and death from COVID-19 for newly diagnosed, at-risk patients, and that it worked equally well against different SARS-CoV-2 variants. John McIntosh, Patrick Fier and colleagues at Merck and Codexis set out to develop a shorter, higher-yielding and sustainable way to synthesize the molecule.

The researchers developed a three-step synthesis of molnupiravir from a sugar molecule called ribose. They identified enzymes or chemical treatments to sequentially add the appropriate chemical groups to ribose to generate the molecule. For the second step of the synthesis, the team identified bacterial enzymes that weakly catalyzed the desired reactions. Using in vitro evolution, they greatly enhanced these enzymes鈥� activities. The new synthetic route, which also included a phosphate recycling strategy, was 70% shorter and had a seven-fold higher overall yield than the original route.

The authors acknowledge funding from聽.

###

The American Chemical 中国365bet中文官网 (ACS) is a nonprofit organization founded in 1876 and chartered by the U.S. Congress. ACS is committed to improving all lives through the transforming power of chemistry. Its mission is to advance scientific knowledge, empower a global community and champion scientific integrity, and its vision is a world built on science. The 中国365bet中文官网 is a global leader in promoting excellence in science education and providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, e-books and weekly news periodical聽Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a leader in scientific information solutions, its CAS division partners with global innovators to accelerate breakthroughs by curating, connecting and analyzing the world鈥檚 scientific knowledge. ACS鈥� main offices are in Washington, D.C., and Columbus, Ohio.

Registered journalists can subscribe to the to access embargoed and public science press releases. For media inquiries, contact newsroom@acs.org.

Note: ACS does not conduct research but publishes and publicizes peer-reviewed scientific studies.

Media Contact

ACS Newsroom
newsroom@acs.org

###

La sociedad American Chemical 中国365bet中文官网 (ACS) es una organizaci贸n sin fines de lucro fundada en 1876 y aprobada por el Congreso de los Estados Unidos. La ACS se ha comprometido a mejorar la vida de todas las personas mediante la transformaci贸n del poder de la qu铆mica. Su misi贸n es promover el conocimiento cient铆fico, empoderar a la comunidad global y defender la integridad cient铆fica, y su visi贸n es un mundo construido bas谩ndose en la ciencia. La Sociedad es l铆der mundial en la promoci贸n de la excelencia en la educaci贸n cient铆fica y en el acceso a informaci贸n e investigaci贸n relacionadas con la qu铆mica a trav茅s de sus m煤ltiples soluciones de investigaci贸n, publicaciones revisadas por expertos, conferencias cient铆ficas, libros electr贸nicos y noticias semanales peri贸dicas de Chemical & Engineering News. Las revistas de la ACS se encuentran entre las m谩s citadas, las m谩s fiables y las m谩s le铆das en la literatura cient铆fica; sin embargo, la propia ACS no realiza investigaci贸n qu铆mica. Como l铆der en soluciones de informaci贸n cient铆fica, su divisi贸n CAS se asocia con innovadores internacionales para acelerar los avances mediante la preservaci贸n, la conexi贸n y el an谩lisis de los conocimientos cient铆ficos del mundo. Las sedes principales de la ACS se encuentran en Washington, D.C., y Columbus, Ohio.

Los periodistas registrados pueden suscribirse al en EurekAlert! para acceder a comunicados de prensa p煤blicos y retenidos.聽 Para consultas de los medios, comun铆quese con newsroom@acs.org.

Nota: ACS no realiza investigaciones, pero publica y divulga estudios cient铆ficos revisados por expertos.鈥�

A new synthetic route could help ensure an adequate supply of molnupiravir, a promising antiviral drug for COVID-19.
A new synthetic route could help ensure an adequate supply of molnupiravir, a promising antiviral drug for COVID-19.
Credit: Copyright 漏 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A. All rights reserved.
View larger image